2025 Q4 -tulosraportti
56 päivää sitten
‧36 min
1,00 NOK/osake
Viimeisin osinko
28,65%Tuotto/v
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 221 | - | - | ||
| 5 854 | - | - | ||
| 3 196 | - | - | ||
| 810 | - | - | ||
| 1 714 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 26.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
11 t sitten11 t sitten◦ Today at #AACR2026, our senior scientist, Ingvild Sørum Leikfoss presented additional immunogenicity data from our VB-C-03 trial and the results are compelling. 100% of evaluable patients in the 6 mg and 9 mg dose groups showed HPV16-specific T-cell immune responses to abi-suva in combination with pembrolizumab. Responses were rapid, robust and durable, with a demonstrated persistence into the last analyzed timepoint at the completed end-of-treatment. Our VB-C-03 trial demonstrated a confirmed objective response rate of 38.5% in patients with HPV16+ recurrent or metastatic head and neck cancer, where standard of care achieves an obiective response rate of only ~19% and we believe abi-suva can make a real difference for these patients., These data give us strong confidence as we move into the Abili-T Phase Il randomized trial G The poster is available for viewing in the "R&D" section of Nykode's website https://lnkd.in/eh4Nrx76 #Nykode #abisuva #HNSCC #HPV16 #CancerVaccine #lmmunotherapy #AACR2026 https://www.linkedin.com/posts/nykode_scientific-papers-and-presentations-nykode-activity-7452434758468456448-V-cn?utm_source=share&utm_medium=member_android&rcm=ACoAAGGSC24B2EXoI8xUZIcaQ9SFwUPmSQJHIyU
·11 t sittenAnything new since yesterday?·10 t sittenTonight, the actual data was presented at the AACR conference. Here's the most important: Double effect: The data confirms an objective response rate (ORR) of 38.5%. In comparison, today's standard treatment only yields ~19%. Nykode thus doubles the effect. Dose selection: They have now locked the dosage to 6 mg and 9 mg. The data showed that 100% of patients in these groups achieved a strong and lasting immune response. T-cell proof: New graphs (TCR sequencing) prove that the vaccine creates many different types of 'soldiers' that survive in the blood throughout the entire treatment. This is technically impressive and distinguishes them from competitors. Operational status: They confirmed tonight that the study centers are now open, and they maintain the goal of the first patient dosed now in Q2 2026. Yesterday we learned that things were going well – tonight we received the scientific evidence for why things are going so well!
·19 t sittenFor what it's worth - Claude's interpretation of the Nykode presentation at AACR Objections are welcome as I am not a specialist in this This VB-C-016 AACR 2026 presentation from Nykode delivers strong data supporting partnership potential with MSD. Here's why: 🎯 DIRECT VALIDATION OF PEMBROLIZUMAB COMPATIBILITY Proven synergy with Keytruda The study shows that the VB10.16 + pembrolizumab combination: Induced HPV16-specific immune responses in 10/11 OPC patients Showed strong and durable T-cell expansion Demonstrated both amplified and de novo T-cell responses This proves that Nykode's technology works synergistically with MSD's flagship molecule. 📊 KEY DATA SUPPORTING PARTNERSHIP 1. Robust immune activation 100% response in the high-dose group (9 mg, n=5) 91% response in the total population (10/11 patients) Strong HPV16 E6/E7-specific T-cell responses were observed 2. Durable immune memory T-cell responses were long-lasting and demonstrated at high magnitude Individual case studies show persistent expansion of specific clones Months of sustained response 3. Safety profile The combination was well tolerated without unexpected safety signals - critical for future development. 🤝 STRATEGIC VALUE FOR MSD A. Differentiation in a competitive market While MSD is concerned about ivonescimab competition, VB10.16 + pembrolizumab offers a completely unique mechanism Personalized neoantigen approach that MSD has not internalized HPV+ tumors represent a large market (oropharyngeal, cervical, anal cancer) B. Expansion of pembrolizumab franchise Adjuvant setting - where MSD is increasing focus Combination data that can support new indications Proof-of-concept for vaccine + checkpoint inhibitor synergy C. Pipeline validation This data shows that Nykode's platform can deliver, making VB10.NEO (personalized neoantigens) even more attractive for MSD's broader oncology portfolio. 🎯 PRACTICAL NEXT STEPS Immediate opportunities: VB10.16 + pembrolizumab phase 2 in HPV+ cancer VB10.NEO combinations in adjuvant setting Platform evaluation for other Keytruda combinations Strategic positioning: Nykode can offer MSD what they need: innovative differentiation MSD can offer Nykode what they need: global reach and regulatory expertise 🔥 CONCLUSION This presentation is golden for potential MSD discussions because it: ✅ Proves Keytruda compatibility ✅ Shows robust clinical efficacy ✅ Demonstrates platform potential ✅ Addresses MSD's need for differentiation Timing is perfect - MSD's AACR focus on combinations + Nykode's proven data = natural conversation about partnership.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
56 päivää sitten
‧36 min
1,00 NOK/osake
Viimeisin osinko
28,65%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 11 t sitten11 t sitten◦ Today at #AACR2026, our senior scientist, Ingvild Sørum Leikfoss presented additional immunogenicity data from our VB-C-03 trial and the results are compelling. 100% of evaluable patients in the 6 mg and 9 mg dose groups showed HPV16-specific T-cell immune responses to abi-suva in combination with pembrolizumab. Responses were rapid, robust and durable, with a demonstrated persistence into the last analyzed timepoint at the completed end-of-treatment. Our VB-C-03 trial demonstrated a confirmed objective response rate of 38.5% in patients with HPV16+ recurrent or metastatic head and neck cancer, where standard of care achieves an obiective response rate of only ~19% and we believe abi-suva can make a real difference for these patients., These data give us strong confidence as we move into the Abili-T Phase Il randomized trial G The poster is available for viewing in the "R&D" section of Nykode's website https://lnkd.in/eh4Nrx76 #Nykode #abisuva #HNSCC #HPV16 #CancerVaccine #lmmunotherapy #AACR2026 https://www.linkedin.com/posts/nykode_scientific-papers-and-presentations-nykode-activity-7452434758468456448-V-cn?utm_source=share&utm_medium=member_android&rcm=ACoAAGGSC24B2EXoI8xUZIcaQ9SFwUPmSQJHIyU·11 t sittenAnything new since yesterday?·10 t sittenTonight, the actual data was presented at the AACR conference. Here's the most important: Double effect: The data confirms an objective response rate (ORR) of 38.5%. In comparison, today's standard treatment only yields ~19%. Nykode thus doubles the effect. Dose selection: They have now locked the dosage to 6 mg and 9 mg. The data showed that 100% of patients in these groups achieved a strong and lasting immune response. T-cell proof: New graphs (TCR sequencing) prove that the vaccine creates many different types of 'soldiers' that survive in the blood throughout the entire treatment. This is technically impressive and distinguishes them from competitors. Operational status: They confirmed tonight that the study centers are now open, and they maintain the goal of the first patient dosed now in Q2 2026. Yesterday we learned that things were going well – tonight we received the scientific evidence for why things are going so well!
- ·19 t sittenFor what it's worth - Claude's interpretation of the Nykode presentation at AACR Objections are welcome as I am not a specialist in this This VB-C-016 AACR 2026 presentation from Nykode delivers strong data supporting partnership potential with MSD. Here's why: 🎯 DIRECT VALIDATION OF PEMBROLIZUMAB COMPATIBILITY Proven synergy with Keytruda The study shows that the VB10.16 + pembrolizumab combination: Induced HPV16-specific immune responses in 10/11 OPC patients Showed strong and durable T-cell expansion Demonstrated both amplified and de novo T-cell responses This proves that Nykode's technology works synergistically with MSD's flagship molecule. 📊 KEY DATA SUPPORTING PARTNERSHIP 1. Robust immune activation 100% response in the high-dose group (9 mg, n=5) 91% response in the total population (10/11 patients) Strong HPV16 E6/E7-specific T-cell responses were observed 2. Durable immune memory T-cell responses were long-lasting and demonstrated at high magnitude Individual case studies show persistent expansion of specific clones Months of sustained response 3. Safety profile The combination was well tolerated without unexpected safety signals - critical for future development. 🤝 STRATEGIC VALUE FOR MSD A. Differentiation in a competitive market While MSD is concerned about ivonescimab competition, VB10.16 + pembrolizumab offers a completely unique mechanism Personalized neoantigen approach that MSD has not internalized HPV+ tumors represent a large market (oropharyngeal, cervical, anal cancer) B. Expansion of pembrolizumab franchise Adjuvant setting - where MSD is increasing focus Combination data that can support new indications Proof-of-concept for vaccine + checkpoint inhibitor synergy C. Pipeline validation This data shows that Nykode's platform can deliver, making VB10.NEO (personalized neoantigens) even more attractive for MSD's broader oncology portfolio. 🎯 PRACTICAL NEXT STEPS Immediate opportunities: VB10.16 + pembrolizumab phase 2 in HPV+ cancer VB10.NEO combinations in adjuvant setting Platform evaluation for other Keytruda combinations Strategic positioning: Nykode can offer MSD what they need: innovative differentiation MSD can offer Nykode what they need: global reach and regulatory expertise 🔥 CONCLUSION This presentation is golden for potential MSD discussions because it: ✅ Proves Keytruda compatibility ✅ Shows robust clinical efficacy ✅ Demonstrates platform potential ✅ Addresses MSD's need for differentiation Timing is perfect - MSD's AACR focus on combinations + Nykode's proven data = natural conversation about partnership.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 221 | - | - | ||
| 5 854 | - | - | ||
| 3 196 | - | - | ||
| 810 | - | - | ||
| 1 714 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 26.2.2025 |
2025 Q4 -tulosraportti
56 päivää sitten
‧36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 26.2.2025 |
1,00 NOK/osake
Viimeisin osinko
28,65%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 11 t sitten11 t sitten◦ Today at #AACR2026, our senior scientist, Ingvild Sørum Leikfoss presented additional immunogenicity data from our VB-C-03 trial and the results are compelling. 100% of evaluable patients in the 6 mg and 9 mg dose groups showed HPV16-specific T-cell immune responses to abi-suva in combination with pembrolizumab. Responses were rapid, robust and durable, with a demonstrated persistence into the last analyzed timepoint at the completed end-of-treatment. Our VB-C-03 trial demonstrated a confirmed objective response rate of 38.5% in patients with HPV16+ recurrent or metastatic head and neck cancer, where standard of care achieves an obiective response rate of only ~19% and we believe abi-suva can make a real difference for these patients., These data give us strong confidence as we move into the Abili-T Phase Il randomized trial G The poster is available for viewing in the "R&D" section of Nykode's website https://lnkd.in/eh4Nrx76 #Nykode #abisuva #HNSCC #HPV16 #CancerVaccine #lmmunotherapy #AACR2026 https://www.linkedin.com/posts/nykode_scientific-papers-and-presentations-nykode-activity-7452434758468456448-V-cn?utm_source=share&utm_medium=member_android&rcm=ACoAAGGSC24B2EXoI8xUZIcaQ9SFwUPmSQJHIyU·11 t sittenAnything new since yesterday?·10 t sittenTonight, the actual data was presented at the AACR conference. Here's the most important: Double effect: The data confirms an objective response rate (ORR) of 38.5%. In comparison, today's standard treatment only yields ~19%. Nykode thus doubles the effect. Dose selection: They have now locked the dosage to 6 mg and 9 mg. The data showed that 100% of patients in these groups achieved a strong and lasting immune response. T-cell proof: New graphs (TCR sequencing) prove that the vaccine creates many different types of 'soldiers' that survive in the blood throughout the entire treatment. This is technically impressive and distinguishes them from competitors. Operational status: They confirmed tonight that the study centers are now open, and they maintain the goal of the first patient dosed now in Q2 2026. Yesterday we learned that things were going well – tonight we received the scientific evidence for why things are going so well!
- ·19 t sittenFor what it's worth - Claude's interpretation of the Nykode presentation at AACR Objections are welcome as I am not a specialist in this This VB-C-016 AACR 2026 presentation from Nykode delivers strong data supporting partnership potential with MSD. Here's why: 🎯 DIRECT VALIDATION OF PEMBROLIZUMAB COMPATIBILITY Proven synergy with Keytruda The study shows that the VB10.16 + pembrolizumab combination: Induced HPV16-specific immune responses in 10/11 OPC patients Showed strong and durable T-cell expansion Demonstrated both amplified and de novo T-cell responses This proves that Nykode's technology works synergistically with MSD's flagship molecule. 📊 KEY DATA SUPPORTING PARTNERSHIP 1. Robust immune activation 100% response in the high-dose group (9 mg, n=5) 91% response in the total population (10/11 patients) Strong HPV16 E6/E7-specific T-cell responses were observed 2. Durable immune memory T-cell responses were long-lasting and demonstrated at high magnitude Individual case studies show persistent expansion of specific clones Months of sustained response 3. Safety profile The combination was well tolerated without unexpected safety signals - critical for future development. 🤝 STRATEGIC VALUE FOR MSD A. Differentiation in a competitive market While MSD is concerned about ivonescimab competition, VB10.16 + pembrolizumab offers a completely unique mechanism Personalized neoantigen approach that MSD has not internalized HPV+ tumors represent a large market (oropharyngeal, cervical, anal cancer) B. Expansion of pembrolizumab franchise Adjuvant setting - where MSD is increasing focus Combination data that can support new indications Proof-of-concept for vaccine + checkpoint inhibitor synergy C. Pipeline validation This data shows that Nykode's platform can deliver, making VB10.NEO (personalized neoantigens) even more attractive for MSD's broader oncology portfolio. 🎯 PRACTICAL NEXT STEPS Immediate opportunities: VB10.16 + pembrolizumab phase 2 in HPV+ cancer VB10.NEO combinations in adjuvant setting Platform evaluation for other Keytruda combinations Strategic positioning: Nykode can offer MSD what they need: innovative differentiation MSD can offer Nykode what they need: global reach and regulatory expertise 🔥 CONCLUSION This presentation is golden for potential MSD discussions because it: ✅ Proves Keytruda compatibility ✅ Shows robust clinical efficacy ✅ Demonstrates platform potential ✅ Addresses MSD's need for differentiation Timing is perfect - MSD's AACR focus on combinations + Nykode's proven data = natural conversation about partnership.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 221 | - | - | ||
| 5 854 | - | - | ||
| 3 196 | - | - | ||
| 810 | - | - | ||
| 1 714 | - | - |
Välittäjätilasto
Dataa ei löytynyt